AF
SYRE icon

Amalgamated Financial’s Spyre Therapeutics SYRE Stock Holding History

Amalgamated Financial’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$11K Buy
+195
New +$16.4K ﹤0.01% 2882

Other funds holding SYRE

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Amalgamated Financial's SYRE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Spyre Therapeutics (SYRE) in Q1 2022: 195 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #2882 among its holdings.

83 funds tracked by Wall St. Rank hold SYRE as of Q1 2022.

  • Amalgamated Financial held 195 shares of Spyre Therapeutics worth $11K as of Q1 2022.
  • Spyre Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Spyre Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2882 holding.
  • 83 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.